Skip to main content
. 2023 Apr 25;381:e074572. doi: 10.1136/bmj-2022-074572

Fig 4.

Fig 4

Relative risk of molnupiravir compared with no treatment on post-acute sequelae of covid-19 according to vaccination status and primary SARS-CoV-2 infection or reinfection. Outcomes were ascertained 30 days after a first SARS-CoV-2 positive test result between 5 January 2022 and 15 January 2023 until end of follow-up. CI=confidence interval